These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16539643)

  • 81. Rituximab for humoral rejection after kidney transplantation: an update.
    Rostaing L; Guilbeau-Frugier C; Kamar N
    Transplantation; 2009 Apr; 87(8):1261. PubMed ID: 19384176
    [No Abstract]   [Full Text] [Related]  

  • 82. Significance of intragraft CD138+ lymphocytes and p-S6RP in pediatric kidney transplant biopsies.
    Tsai EW; Wallace WD; Gjertson DW; Reed EF; Ettenger RB
    Transplantation; 2010 Oct; 90(8):875-81. PubMed ID: 20736897
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Successful induction and maintenance of long-term remission in a child with chronic relapsing autoimmune hemolytic anemia using rituximab.
    Gottardo NG; Baker DL; Willis FR
    Pediatr Hematol Oncol; 2003; 20(7):557-61. PubMed ID: 12959862
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring.
    Knechtle SJ; Pascual J; Bloom DD; Torrealba JR; Jankowska-Gan E; Burlingham WJ; Kwun J; Colvin RB; Seyfert-Margolis V; Bourcier K; Sollinger HW
    Am J Transplant; 2009 May; 9(5):1087-98. PubMed ID: 19344431
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The Effect of Histological CD20-Positive B Cell Infiltration in Acute Cellular Rejection on Kidney Transplant Allograft Survival.
    Jiang Y; Wang R; Wang H; Huang H; Peng W; Qiu W; Zhou J; Chen J
    J Immunol Res; 2016; 2016():7473239. PubMed ID: 28058267
    [No Abstract]   [Full Text] [Related]  

  • 86. Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation.
    Kamar N; Lavayssière L; Muscari F; Selves J; Guilbeau-Frugier C; Cardeau I; Esposito L; Cointault O; Nogier MB; Peron JM; Otal P; Fort M; Rostaing L
    World J Gastroenterol; 2009 Jul; 15(27):3426-30. PubMed ID: 19610146
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group.
    Woodle ES; Thistlethwaite JR; Gordon JH; Laskow D; Deierhoi MH; Burdick J; Pirsch JD; Sollinger H; Vincenti F; Burrows L; Schwartz B; Danovitch GM; Wilkinson AH; Shaffer D; Simpson MA; Freeman RB; Rohrer RJ; Mendez R; Aswad S; Munn SR; Wiesner RH; Delmonico FL; Neylan J; Whelchel J
    Transplantation; 1996 Sep; 62(5):594-9. PubMed ID: 8830821
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Use of monoclonal antibodies in renal transplantation.
    van den Hoogen MW; Hilbrands LB
    Immunotherapy; 2011 Jul; 3(7):871-80. PubMed ID: 21751955
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Desensitization with plasmapheresis and anti-Cd20 for ABO incompatible kidney transplantation from living donor: experience of a single center in Italy.
    Silvestre C; Furian L; Marson P; Tison T; Valente M; Marchini F; Rossi B; Bonfante L; Valerio F; Cozzi E; Rigotti P
    Transplant Proc; 2014 Sep; 46(7):2209-13. PubMed ID: 25242753
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
    Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.
    Budde K; Bosmans JL; Sennesael J; Zeier M; Pisarski P; Schütz M; Fischer W; Neumayer HH; Glander P
    Clin Nephrol; 2007 Mar; 67(3):164-75. PubMed ID: 17390741
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Bortezomib in kidney transplant recipients with antibody mediated rejection: three case reports.
    Wong W; Lee RA; Saidman SL; Smith RN; Zorn E
    Clin Transpl; 2009; ():401-5. PubMed ID: 20524305
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
    Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
    Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts.
    Hippen BE; DeMattos A; Cook WJ; Kew CE; Gaston RS
    Am J Transplant; 2005 Sep; 5(9):2248-52. PubMed ID: 16095505
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients.
    Levi ME; Quan D; Ho JT; Kleinschmidt-Demasters BK; Tyler KL; Grazia TJ
    Clin Transplant; 2010; 24(2):223-8. PubMed ID: 19659514
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection.
    Theruvath TP; Saidman SL; Mauiyyedi S; Delmonico FL; Williams WW; Tolkoff-Rubin N; Collins AB; Colvin RB; Cosimi AB; Pascual M
    Transplantation; 2001 Jul; 72(1):77-83. PubMed ID: 11468538
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab.
    Baran DA; Lubitz S; Alvi S; Fallon JT; Kaplan S; Galin I; Correa R; Courtney MC; Chan M; Spielvogel D; Lansman SL; Gass AL
    Transplant Proc; 2004 Dec; 36(10):3164-6. PubMed ID: 15686719
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis.
    Sawada T; Fuchinoue S; Teraoka S
    Transplantation; 2002 Nov; 74(9):1207-10. PubMed ID: 12451255
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
    Fehr T; Rüsi B; Fischer A; Hopfer H; Wüthrich RP; Gaspert A
    Transplantation; 2009 Jun; 87(12):1837-41. PubMed ID: 19543061
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Targeting B cells and antibody in transplantation.
    Clatworthy MR
    Am J Transplant; 2011 Jul; 11(7):1359-67. PubMed ID: 21668625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.